<DOC>
	<DOC>NCT00395057</DOC>
	<brief_summary>This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration</brief_summary>
	<brief_title>A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>50 years or older with "wet" AMD as determined by an ophthalmologist decrease in visual acuity (20/40 to 20/640) in at least one eye Uncontrolled systemic disease History of heart attack or stroke within one year of study entry Symptomatic coronary artery disease Cataracts that interfere with vision</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>